<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="../images/favicon.png" type="image/x-icon">
  <title>Childhood Bronchial Asthma</title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="../style.css">
  <link rel="stylesheet" href="../notes.css">

</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="../index.html">
   <div class="home-navigation">
      mtr<span class="logo-dot">.</span>
    </div>
  </a>


    <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="../index.html">Home</a>
      </li>

      <li class="menu__item">
        <a class="menu__link" href="../about-temp2.html">About</a>
      </li>
    </ul>
  </nav>
  
      <!-- Toggle switch for dark mode -->
      <div class="dark-mode-toggle">
        <label class="switch-toggle">
            <input type="checkbox" id="dark-mode-toggle-checkbox">
            <span class="toggle-slider"></span>
        </label>
      </div>

      <!-- Progress Bar  -->
      <div id="progress-container">
        <div id="progress-bar"></div>
    </div>
      
<!-- SIDEBAR -->
<div id="sidebar" class="sidebar">
  <button id="closeSidebarBtn" class="btn toggle-btn close-btn">Close</button>
  <ul class="sidebar-menu toggle-menu">
    <!-- Add the list of topics dynamically using JavaScript -->
  </ul>
</div>

<!-- Toggle button to open the sidebar -->
<button id="toggleSidebarBtn" class="btn toggle-btn">&#9776;</button>

<!-- END OF SIDEBAR -->

  <main class="page-container">
    <div class="contribute-cta">
      <p>Help make this betterüíú</p>
      <span><a href="../contribute.html">Contribute here</a> </span>
    </div>


  <!-- TOPIC AND IMAGE CONTAINER  -->

  <h1>Childhood Bronchial Asthma</h1>


  <!-- END OF TOPIC AND IMAGE CONTAINER  -->
  


    <article class="notes">
        <a id='top'></a>
    <article>

          <!-- LEARNING OBJECTIVES CONTAINER  -->
              <div class="custom-card" id="custom-card-1">
                <div class="icon"><img src="../images/icons/light-bulb.png" alt="Icon" class="icon"></div>
                <div class="title"> 
                  <h2>What You Will Learn</h2>
                </div>
                <div class="line">
                  <p>After reading this note, you should be able to...</p>
                </div>
                <div class="content">
                  <ul>
                    <li><i>This content is not available yet.</i></li>
                </ul>
                </div>
                <div class="read-more" onclick="toggleContent('custom-card-1')">Read More üç™</div>
              </div>
            
          <!-- END OF LEARNING OBJECTIVES CONTAINER  -->
        
        
          <!-- SHOW AND HIDE OUTLINE CONTAINER  -->
            <div class="outline2">
        
              <input type="radio" name="control-2" id="show-2">
              <label for="show-2">üêµ&nbsp; &nbsp;Show Outline</label>
              <input type="radio" name="control-2" id="hide-2">
              <label for="hide-2">üôà&nbsp; &nbsp; Hide Outline</label>
              <div class="contents">
                <div class="icon-box">
                  <!-- Replace 'path/to/your/icon.png' with the actual path to your PNG icon -->
                  <img src="../images/icons/book.png" alt="Icon" class="icon">
                </div>
                <div id="tableOfContents">
                    <ol id="tocList"></ol>
                </div>
              </div>
             <div>
        
        <!-- END OF SHOW AND HIDE OUTLINE CONTAINER  -->
        
        
          <br>
        
            <!-- BEGINNING OF NOTE -->
        
      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'>Introduction</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
                <li><strong>Definition, contentious</strong>; None universally accepted</li>
                <li>The word is a derivative of a Greek word which means <strong>‚ÄúTo pant.‚Äù</strong></li>
                <li><strong>Contents of a valid definition:</strong>
                    <ul>
                        <li>Presence of <strong>chronic recurrent cough</strong></li>
                        <li><strong>Episodic breathlessness</strong></li>
                        <li>Recurrent <strong>wheezing</strong> (polyphonic, often expiratory)</li>
                        <li><strong>Chest tightness & BHR</strong> with widespread, variable & often reversible airflow obstruction</li>
                        <li><strong>Chronic airway inflammation</strong></li>
                        <li><strong>Cellular correlates/orchestrators:</strong> mast cells, eosinophils, T-lymphocytes, and macrophages</li>
                    </ul>
                </li>
                <li><strong>A fairly all-encompassing definition:</strong></li>
                <blockquote>‚ÄúChronic inflammatory disorder of the airways in which many cells (including mast cells and eosinophils) play a role. In susceptible individuals, this inflammation causes symptoms usually associated with widespread but variable airflow obstruction that is often reversible, either spontaneously or with treatment, and causes an associated increase in airway responsiveness to a variety of stimuli.‚Äù</blockquote>
            </ul>
            
            <ul>
                <li><strong>Other definitions:</strong></li>
                <ul>
                    <li>‚ÄúEpisodic wheeze and/or cough in a clinical setting in which asthma is <strong>most likely</strong> and other rarer conditions (causing episodic wheeze and/or cough) have been excluded.‚Äù</li>
                    <li>‚ÄúEosinophil-mediated airway inflammation.‚Äù</li>
                    <li>‚Äú...a multifactorial disease that is likely to be the result of interactions between a genetically determined predisposition to allergic diseases and environmental factors that serve to enhance allergic inflammation and target inflammation to the lower airway.‚Äù</li>
                </ul>
                <li><strong>Genetic factors:</strong></li>
                <ul>
                    <li>Regulation of cytokines and control of eosinophil-mediated inflammation</li>
                    <li>Polymorphism of the gene that regulates airway tone (e.g., beta-adrenergic receptors) and repair mechanisms for acute injuries</li>
                </ul>
                <li><strong>Environmental factors:</strong></li>
                <ul>
                    <li>Exposure to microbial products and allergens in early life, which may play a major role in the development of the immune system so that allergies are less likely to occur</li>
                    <li>Once allergy develops, severe acute viral (RSV bronchiolitis) or chronic lower respiratory infections (ADV, mycoplasmal, and Chlamydial) cause lung damage and target allergic lower airway inflammation, BHR, and hence the development of asthma</li>
                    <li><strong>Gern JE & Lemanske RF, 2003</strong></li>
                </ul>
            </ul>
            
                        <!-- image here -->
                        <div class="image-container">
                            <img src="../figures/childhood-bronchial-asthma (1).png" alt="" onclick="openModal(this)">
                            <div class="caption">Interaction between environmental and genetic factors</div>
                          </div>
                          
                          <div id="myModal" class="modal">
                            <span class="close" onclick="closeModal()">&times;</span>
                            <img class="modal-content" id="modalImage">
                            <div id="caption" class="caption">Interaction between environmental and genetic factors</div>
                          </div>
        </div>
      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'>Asthma-related Terminologies</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
                <li><strong>Hyperresponsiveness (Hyperreactivity):</strong> The propensity of the airway to constrict too easily and too much following exposure to a standard trigger agent or allergen.</li>
                <li><strong>Atopy:</strong> The ability to develop IgE to innocuous and frequently ubiquitous environmental agents such as pollens, mites, and molds.</li>
                <li><strong>Vital capacity:</strong> The largest volume a subject can expire after a single maximal inspiration.</li>
                <li><strong>Forced vital capacity (FVC):</strong> The vital capacity when the expiration is performed as rapidly and as completely as possible.</li>
                <li><strong>Forced expiratory volume in one second (FEV1):</strong> The volume expired during the first second of Forced Vital Capacity.</li>
                <li><strong>FEV1/FVC &gt; 75%:</strong>
                    <ul>
                        <li>This ratio is reduced in obstructive airway diseases like asthma, emphysema, and bronchitis.</li>
                    </ul>
                </li>
                <li><strong>Peak expiratory flow rate (PEFR):</strong> The maximum expiratory flow rate achieved during a forced expiration.</li>
                <ul>
                    <li>PEFR is more convenient to measure than FEV1.</li>
                </ul>
                <li><strong>Airway responsiveness:</strong></li>
                <ul>
                    <li>The response of the airways to provoking stimuli, usually expressed as the provoking dose of a bronchoconstrictor like histamine or methacholine (i.e., concentration causing a 20% fall in FEV1), or the slope of a dose-response curve.</li>
                </ul>
            </ul>
            

        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>Epidemiologic Risk Factors</a>
          </h2>
        </header>
        <div class='body'>

            <strong>Host factors:</strong>
            <ul>
                <li>Age</li>
                <li>Gender</li>
                <li>Race</li>
                <li>Genetics of asthma</li>
            </ul>
            
            <strong>Environmental Factors:</strong>
            <ul>
                <li>Socioeconomic factors</li>
                <li>Seasonal</li>
                <li>Exposure to viral infections</li>
                <li>Exposure to passive smoke</li>
                <li>Early artificial feeds</li>
                <li>Family history of atopy/asthma</li>
            </ul>
            
            <h4>Host Factor</h4>
            <ul>
                <li><strong>Twins study:</strong> Effect of genetic factors is about 35% to 70%</li>
                <li>No gene or genes involved in the heritability of atopy or asthma has been identified with certainty.</li>
                <li>Results suggest involvement of multiple genes and chromosomal regions likely to harbor asthma susceptibility genes.</li>
            </ul>
            
            <h4>Environmental Factors</h4>
            
            <strong>Allergens:</strong>
            <ul>
                <li><strong>Outdoor:</strong> Pollen (tree, grass, and flower), molds (<em>Aspergillus fumigatus</em> and others)</li>
                <li><strong>Indoor:</strong> Mites (<em>Dermatophagoides pteronyssinus, D. farina</em>), Animals (cats, dogs, birds), cockroaches</li>
            </ul>
            
            <strong>Viral respiratory infections:</strong>
            <ul>
                <li>Mainly RSV</li>
                <li>Others include: Rhinovirus, Parainfluenza virus</li>
            </ul>
            
        </div>
      </section>

      <section id='header-4'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-4'>Pathogenesis</a>
          </h2>
        </header>
        <div class='body'>
            <h4>Airway Hyperresponsiveness</h4>

            <ul>
                <li><strong>Asthma-related inflammatory cells</strong> act in tandem to initiate, orchestrate, and sustain airway hyperresponsiveness (AHR) via the release of several inflammatory mediators.</li>
                <li><strong>BAL & biopsy studies</strong> suggest the following asthma-related inflammatory cells & mediators play important roles (3 granulocytes & several non-granulocytes):</li>
            </ul>
            
            <ol>
                <li><strong>Mast cells (granulocyte)</strong> - Histamine</li>
                <li><strong>Eosinophils</strong> (earliest asthma-related granulocyte!) - Major Basic Protein (MBP) and Monocyte Chemoattractant Protein (MCP)</li>
                <li><strong>Neutrophils</strong> (uncertain role)</li>
                <li><strong>Alveolar macrophages</strong> (from blood monocytes) & T-lymphocytes:
                    <ul>
                        <li><strong>Cytokines/growth factors:</strong> IL-3, IL-4, IL-5, IL-1, IL-6, TNF-alpha, GM-CSF, PDGF, and TGF-beta</li>
                        <li><strong>Products of arachidonic acid pathways:</strong> Prostaglandins, thromboxanes, leukotrienes</li>
                        <li><strong>Platelet-activating factor (PAF)</strong></li>
                    </ul>
                </li>
                <li><strong>Airway epithelial cells:</strong> Endothelins, pro-inflammatory cytokines/chemokines, growth factors like PDGF, GM-CSF, Nitric Oxide, and locally generated non-adrenergic non-cholinergic (NANC) nervous system neuropeptides</li>
            </ol>
            
            <ul>
                <li><strong>Endothelins:</strong> Potent vaso- & bronchoconstrictor peptides along with growth factors like GM-CSF, may play a role in fixed airway narrowing via stimulation of smooth muscle proliferation & fibrosis.</li>
                <li><strong>Nitric oxide:</strong> A bronchodilator of the NANC nervous system, generated in airway epithelial cells with nitric oxide synthase (NOS, inducible by cytokines); reduces mucosal edema via intraluminal exudation of plasma and sustains inflammation via amplification of Th-2 lymphocyte-mediated response.</li>
                <li><strong>NANC neuropeptides:</strong>
                    <ul>
                        <li><strong>Substance P:</strong> Causes microvascular leakage, mucosal edema, and mucus hypersecretion.</li>
                        <li><strong>Neurokinin A</strong></li>
                    </ul>
                </li>
            </ul>
            
            <h4>Arachidonic Acid as a Source of Airway Prostaglandins, Thromboxanes & Leukotrienes</h4>
            
            <ul>
                <li><strong>Prostaglandins & thromboxanes:</strong> Products of the cyclooxygenase subpathway, while leukotrienes are generated by the lipo-oxygenase enzyme pathway.</li>
                <li><strong>PGD-2:</strong> Capable of producing sustained bronchoconstrictor effects via amplification of the inflammatory process; its importance in asthma pathology remains undefined.</li>
                <li><strong>PGF-2alpha (prostanoid):</strong> Potentiates the effects of histamine on airway caliber and is a potent bronchoconstrictor.</li>
                <li><strong>Prostacyclin:</strong> A vasodilator that contributes to mucosal inflammation/edema & hence bronchoconstriction in humans.</li>
                <li><strong>PGE-2:</strong> A bronchoprotective agent with bronchodilatory properties.</li>
                <li><strong>Pathogenesis:</strong> Likely regulated by the bronchoconstrictive:bronchodilatory prostanoid ratio.</li>
                <li><strong>Thromboxane A-2:</strong> A bronchoconstrictive mediator with a significant role in the late asthmatic response. <strong>OKY-046</strong> has anti-thromboxane effects and may be effective in the late response.</li>
                <li><strong>LTC4, LTD4 & LTE4:</strong> Sulfidopeptides (collectively formerly known as SRSA) with bronchoconstrictive properties via effects on microvascular permeability & mucociliary functions.</li>
                <li><strong>Anti-5-lipooxygenase & anti-LTCs (e.g., Zileuton, Zafirlukast, Montelukast):</strong> These agents are broncho- & nasoprotective against cold air and nasal allergen challenges, respectively.</li>
            </ul>

            <h4>Pathogenesis ‚Äì Target Cells‚Äô Effects of Inflammatory Mediators</h4>

            <ol>
                <li><strong>Airway smooth muscle contraction</strong> ‚Äì Not an increase in response to spasmogens but attributable to:
                    <ul>
                        <li>Diminished responsiveness of beta-adrenoceptors (surgical & post-mortem studies)</li>
                        <li>Possibly due to uncoupling ‚Äì reference to tachyphylaxis in chronic beta-2 agonist usage.</li>
                        <li>Growth factor-related hypertrophy and hyperplasia</li>
                    </ul>
                </li>
                <li><strong>Airway epithelial shedding</strong> ‚Äì Appears as ‚Äúcreola bodies‚Äù in BAL and is predominantly mediated by eosinophil MBP, oxygen-derived free radicals, and several inflammatory cellular proteases.
                    <ul>
                        <li>Effects: Loss of mucosal epithelial barrier function, neural endopeptidases (to degrade mediators), exposure of airway sensory nerves, and enhancement of local reflexes due to loss of epithelial-derived relaxant factor (EDRF).</li>
                    </ul>
                </li>
                <li><strong>Subepithelial fibrosis</strong> ‚Äì Effect of growth factor cytokines like PDGF and TGF-beta derived from macrophages and/or epithelial cells.
                    <ul>
                        <li>Effects: Subepithelial deposits of collagen (type III & V) and myofibroblasts; increased size of basement membrane (this is a consistent finding in fatal asthma).</li>
                    </ul>
                </li>
                <li><strong>Vascular response</strong> (Vasodilatation, Microvascular leakage & Plasma extravasation)
                    <ul>
                        <li>Increased blood flow is important in exercise-induced asthma (EIA) & removal of mediators.</li>
                        <li>Consequences of microvascular leakage & plasma extravasation caused by mediator release include increased airway secretions, decreased mucociliary clearance, generation of new mediators from plasma precursors like kinins, and mucosal edema.</li>
                    </ul>
                </li>
                <li><strong>Mucus hypersecretion</strong>
                    <ul>
                        <li>Possibly a consequence of increased secretory response to mediators associated with neural element stimulation.</li>
                        <li>Viscid mucus plugs from this hypersecretion are a frequent cause of fatal asthma.</li>
                    </ul>
                </li>
            </ol>
            
            <h4>Pathogenesis</h4>
            
            <ul>
                <li><strong>Chronic eosinophilic inflammation</strong></li>
                <li><strong>CD4+ Th2 lymphocytes</strong></li>
                <li><strong>Interleukins</strong></li>
                <li><strong>IgE antibodies</strong> (Allergen-specific)</li>
                <li><strong>Mast cells</strong> (and other effector cells)</li>
                <li><strong>Sensitization:</strong> Years of continued exposure to allergens in early life with asymptomatic inflammation (inducers).</li>
                <li><strong>Early response:</strong> Allergen re-exposure or trigger agents like smoke, exercise, cold air, etc., with consequent mediator release (inciters).</li>
                <li><strong>Late response:</strong> Allergen re-exposure or trigger with consequent prolonged and intense bronchoconstriction due to mediator-associated amplification of the inflammation via further granulocyte activation (mast cells, eosinophils, neutrophils); viral infections are particularly effective in enhancing the late response.</li>
            </ul>
            
            <h4>Pathogenesis: Inducers vs. Inciters</h4>
            
            <ul>
                <li><strong>Inducers (Precipitating)</strong> ‚Äì Continued allergen exposure (for years) in early life causes sensitization with the generation of allergen-specific IgE, asymptomatic inflammation, and bronchial hyperresponsiveness (BHR).
                    <ul>
                        <li>Factors/agents: Viruses, HDM, Fel-D1, Per-A1, pollen, fungi</li>
                    </ul>
                </li>
                <li><strong>Inciters (Triggers)</strong> ‚Äì Re-exposure to allergens, viral or intracellular pathogen (Mycoplasma or Chlamydial) infections, or non-specific environmental agents/irritants like smoke (cigarette or culinary), ozone, physical stimuli like exercise or cold air, endogenous variables like emotional stress, and diurnal variation in beta-2 or nebulized mediators (of weak solutions of histamine or methacholine).</li>
            </ul>
            
            <!-- image here -->
            <div class="image-container">
                <img src="../figures/childhood-bronchial-asthma (2).png" alt="" onclick="openModal(this)">
                <div class="caption">The 2 Asthma phenotypes & the ‚Äúhygiene hypothesis‚Äù</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">The 2 Asthma phenotypes & the ‚Äúhygiene hypothesis‚Äù</div>
              </div>
            

                          <!-- image here -->
            <div class="image-container">
                <img src="../figures/childhood-bronchial-asthma (3).png" alt="" onclick="openModal(this)">
                <div class="caption">The 2 Asthma phenotypes & the ‚Äúhygiene hypothesis‚Äù</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">The 2 Asthma phenotypes & the ‚Äúhygiene hypothesis‚Äù</div>
              </div>
        </div>
      </section>

      <section id='header-5'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-5'>Aetiopathogenesis</a>
          </h2>
        </header>
        <div class='body'>

            <p><strong>Aetiology of asthma</strong> is complex, and multiple environmental and genetic determinants are implicated.</p>
            
                                    <!-- image here -->
                                    <div class="image-container">
                                        <img src="../figures/childhood-bronchial-asthma (2).jpg" alt="" onclick="openModal(this)">
                                        <div class="caption">Predisposing and protective factors</div>
                                      </div>
                                      
                                      <div id="myModal" class="modal">
                                        <span class="close" onclick="closeModal()">&times;</span>
                                        <img class="modal-content" id="modalImage">
                                        <div id="caption" class="caption">Predisposing and protective factors</div>
                                      </div>

            <h4>The Allergic Cascade</h4>
            
            <ul>
                <h4>Sensitization</h4>
                <ul>
                    <li><strong>CD4+ Th2 cells and B cells</strong> interact and produce allergen-specific IgE.</li>
                    <li>Interactions between <strong>CD4 T Cells and B Cells</strong> are important in IgE synthesis.</li>
                    <li><strong>IgE antibodies</strong> synthesized bind to high-affinity IgE receptors on the surface of mast cells in tissue or peripheral-blood basophils, and low-affinity IgE receptors on the surface of lymphocytes, eosinophils, platelets, and macrophages.</li>
                    <li>This process is known as <strong>sensitization</strong>.</li>
                </ul>
                
                <h4>Early Phase Response</h4>
                <ul>
                    <li>When a sensitized individual comes in contact with the same allergen again, there is <strong>molecular bridging of the receptors</strong>.</li>
                    <li>This occurs when the allergen interacts with receptor-bound IgE molecules, causing activation of the cell and the release of preformed and newly generated mediators including histamine, prostaglandins, leukotrienes, and cytokines, among others.</li>
                    <li>Once present in various tissues, mediators may produce various physiological effects, depending on the target organ.</li>
                    <li>The early response involves <strong>mucosal edema and bronchospasm</strong>, producing airway obstruction.</li>
                </ul>
                
                <h4>Late Phase Response</h4>
                <ul>
                    <li>If no intervention occurs, there is an influx of inflammatory cells, mainly eosinophils and neutrophils.</li>
                    <li>This further worsens airway narrowing and consequently increases airflow obstruction.</li>
                </ul>
            </ul>



                        <!-- image here -->
                        <div class="image-container">
                            <img src="../figures/childhood-bronchial-asthma (4).png" alt="" onclick="openModal(this)">
                            <div class="caption">Normal vs asthmatic bronchiole</div>
                          </div>
                          
                          <div id="myModal" class="modal">
                            <span class="close" onclick="closeModal()">&times;</span>
                            <img class="modal-content" id="modalImage">
                            <div id="caption" class="caption">Normal vs asthmatic bronchiole</div>
                          </div>
            

                          <p>The airway obstruction is due to:</p>
                          <ul>
                              <li><strong>The swelling of the airway mucosa</strong> due to inflammation</li>
                              <li><strong>Mucosal edema</strong></li>
                              <li><strong>Mucus plugs</strong> in the airways</li>
                              <li><strong>Bronchospasm</strong> of the muscles around the airways</li>
                          </ul>
                          
                                      <!-- image here -->
            <div class="image-container">
                <img src="../figures/childhood-bronchial-asthma (5).png" alt="" onclick="openModal(this)">
                <div class="caption">Specimen of bronchial mucosa from a subject without asthma (Panel A) and a patient with mild asthma (Panel B) (Hematoxylin and Eosin, x40).</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">Specimen of bronchial mucosa from a subject without asthma (Panel A) and a patient with mild asthma (Panel B) (Hematoxylin and Eosin, x40).</div>
              </div>

              <ul>
                <li>In the subject without asthma, the <strong>epithelium is intact</strong>; there is no thickening of the sub-basement membrane, and there is no cellular infiltrate.</li>
                <li>In contrast, in the patient with mild asthma, there is evidence of <strong>goblet-cell hyperplasia</strong> in the epithelial-cell lining. The <strong>sub-basement membrane is thickened</strong>, with collagen deposition in the submucosal area, and there is a <strong>cellular infiltrate</strong>.</li>
            </ul>
            
            <h4>Airway Remodeling in Asthma</h4>
            <ul>
                <li><strong>Remodeling</strong> entails thickening of the airway walls, with increases in submucosal tissue, the adventitia, and smooth muscle.</li>
                <li>Preventing the progressive loss of lung function in childhood may require <strong>recognition and treatment</strong> of the disease during the first five years of life.</li>
            </ul>

                        <!-- image here -->
                        <div class="image-container">
                            <img src="../figures/childhood-bronchial-asthma (3).jpg" alt="" onclick="openModal(this)">
                            <div class="caption">Pathophysiology of asthma</div>
                          </div>
                          
                          <div id="myModal" class="modal">
                            <span class="close" onclick="closeModal()">&times;</span>
                            <img class="modal-content" id="modalImage">
                            <div id="caption" class="caption">Pathophysiology of asthma</div>
                          </div>


                          <h4>Mechanisms of Virus-Induced Asthma</h4>

                          <ul>
                            <li><strong>Production of virus-specific IgE antibody</strong></li>
                            <li><strong>Enhanced leucocyte inflammatory function</strong></li>
                            <li><strong>Enhancement of factors involved in late phase response to allergen challenge</strong></li>
                            <li><strong>Altered autonomic nervous system</strong>:
                              <ul>
                                <li>Beta-adrenergic blockade</li>
                                <li>Cholinergic stimulation</li>
                              </ul>
                            </li>
                            <li><strong>Damage to airway epithelium</strong>:
                              <ul>
                                <li>Neutral endopeptidase deficiency</li>
                                <li>Loss of endogenous bronchodilator receptors</li>
                                <li>Expression of adhesion molecules (e.g., ICAMs, VCAMs)</li>
                              </ul>
                            </li>
                          </ul>
                          
        </div>
      </section>

      <section id='header-6'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-6'>Diagnosis of Asthma: Clinical Indicators</a>
          </h2>
        </header>
        <div class='body'>

            <h4>General</h4>
            <ul>
                <li>Diagnosis is clinical, but it is not an <strong>‚Äúall-or-none‚Äù diagnosis</strong> due to a wide spectrum of disease severity.</li>
                <li>No radiographic, blood, or histopathologic parameter is diagnostic, but some objective <strong>pulmonary function tests (PFTs)</strong> may be suggestive.</li>
                <li><strong>Clinical Clues</strong> which are by no means exclusive to asthma include:</li>
                <ul>
                    <li><strong>Key Symptoms</strong> -</li>
                    <ul>
                        <li><strong>Cough</strong></li>
                        <li><strong>Wheeze</strong> (polyphonic)</li>
                        <li><strong>Dyspnoea</strong> or shortness of breath</li>
                        <li><strong>Chest tightness</strong></li>
                    </ul>
                    <li>When two or more of these are present, their peculiarities that suggest asthma as the likely morbidity include:</li>
                    <ul>
                        <li><strong>Variability</strong></li>
                        <li><strong>Intermittent nature</strong></li>
                        <li><strong>Nocturnal and seasonal preponderance</strong></li>
                    </ul>
                    <li><strong>Cough-type (or cough-variant) asthma</strong> occurs when cough is the predominant symptom without a wheeze.</li>
                </ul>
            </ul>
            
            <h4>Corroborative Symptoms and Risk Factors</h4>
            <ul>
                <li><strong>Personal or family history of atopic diatheses</strong> (eczema, allergic rhinitis, vernal conjunctivitis)</li>
                <li>Symptom flares following recognized trigger factors like:</li>
                <ul>
                    <li>Viral respiratory infections</li>
                    <li>Dusty chores</li>
                    <li>Physical exertion</li>
                    <li>Tobacco smoke</li>
                    <li>Exposure to animal danders or feathers</li>
                    <li>Rarely, to aspirin, NSAIDs, or beta-blockers</li>
                </ul>
            </ul>
            
            <h4>Physical Signs</h4>
            <ul>
                <li>In between episodes when the child is symptomatic, corroborative physical signs may be absent.</li>
                <li>In those with chronic asthma, residual signs of <strong>hyperinflation</strong> may be seen.</li>
                <li>During acute exacerbations, respiratory distress associated with bilateral, widespread polyphonic expiratory wheeze/rhonchi.</li>
                <li>Objective changes (suggestive of lower airway obstruction) in <strong>PFTs</strong> are best considered under investigative findings.</li>
            </ul>
            
            <h4>Objective Tests of Lung Function</h4>

            <p>Essentially aimed at demonstrating variability of airflow:</p>
            
            <ul>
                <li><strong>% Variability of PEFR and/or FEV1</strong> (Max. PEFR - Min. PEFR / Max. PEFR x 100 = % variability):</li>
                <ul>
                    <li><strong>> 20%</strong> is suggestive but poorly specific.</li>
                </ul>
                <li><strong>15% change (or 10%) in FEV1</strong> after a test, or 20% change in PEFR before and after ‚Äúmeasured‚Äù exercise like 6 minutes of free running to raise pulse rate to > 160/min; PEFR at 10-minute intervals for subsequent 30 minutes.</li>
                <li><strong>15% rise in FEV1 or 20% PEFR</strong> after inhaled <strong>Œ≤<sub>2</sub> agonist</strong> via nebulizer or MDI.</li>
                <li><strong>15% rise in FEV1 or 20% PEFR</strong> after 2 weeks of systemic steroid therapy (oral prednisolone, 1-2 mg/kg).</li>
                <li><strong>Histamine or Metacholine challenge</strong>, then measure FEV1 or PEFR.</li>
                <li>Others:</li>
                <ul>
                    <li><strong>FEV1/FVC</strong></li>
                    <li><strong>FEF 25-75%</strong></li>
                    <li>Specific spirometric pattern</li>
                    <li><strong>Chest X-ray (CXR)</strong></li>
                </ul>
            </ul>
            
            <p><strong>Lung Function tests</strong> are notoriously difficult/not possible in children < 5 years, hence the need for other indices, and if still in doubt, wait until the child is older.</p>

            <h4>Characteristic Patterns of Obstructive & Restrictive Disease as Measured by Spirometry</h4>

            <table class="note-table">
                <thead>
                    <tr>
                        <th>Parameter (<em>Normal range % predicted</em>)</th>
                        <th>Minimum Significant Change after Bronchodilator</th>
                        <th>Obstruction</th>
                        <th>Restriction</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>FVC</strong></td>
                        <td>> 80%<br><strong>+10%</strong></td>
                        <td>N or low</td>
                        <td>Low</td>
                    </tr>
                    <tr>
                        <td><strong>FEV1</strong></td>
                        <td>> 80%<br><strong>+10%</strong></td>
                        <td>Low</td>
                        <td>N or low</td>
                    </tr>
                    <tr>
                        <td><strong>FEV1/FVC</strong></td>
                        <td>> 80%</td>
                        <td>Low</td>
                        <td>High</td>
                    </tr>
                    <tr>
                        <td><strong>FEF25-75</strong></td>
                        <td>> 70%<br><strong>+25%</strong></td>
                        <td>Low</td>
                        <td>Normal, high, or low</td>
                    </tr>
                </tbody>
            </table>
            
            <h4>Indications for Pulmonary Function Tests (PFTs) in Children</h4>
            <ul>
                <li><strong>Recurrent wheezing</strong></li>
                <li><strong>Chronic cough</strong>, especially nocturnal</li>
                <li><strong>Unexplained dyspnoea</strong></li>
                <li><strong>Exercise-induced breathlessness and/or cough</strong></li>
                <li><strong>Coughing & wheezing associated with cold air exposure or weather changes</strong></li>
                <li><strong>Slowly resolving or recurrent bronchitis or bronchiolitis</strong></li>
                <li><strong>Follow-up care and assessment</strong></li>
                <li><strong>Recurrent pneumonia</strong></li>
                <li><strong>Pre-surgery investigation of lobectomy for chronic suppurative lung disease</strong></li>
            </ul>
            
            <p>In general, extrapolations from cohort or controlled studies and expert opinions indicate that the diagnosis of childhood asthma (including those in whom Pulmonary Function Testing (PFT) is not possible) is based on:</p>
            <ul>
                <li><strong>Identifying any of the key symptoms</strong> and giving careful consideration to <strong>alternative diagnoses</strong> (see table below).</li>
                <li><strong>Repeating assessment after a treatment trial</strong> and questioning the diagnosis if treatment is ineffective.</li>
            </ul>

                        <!-- image here -->
                        <div class="image-container">
                            <img src="../figures/childhood-bronchial-asthma (4).jpg" alt="" onclick="openModal(this)">
                            <div class="caption">Diagnosis of asthma in children</div>
                          </div>
                          
                          <div id="myModal" class="modal">
                            <span class="close" onclick="closeModal()">&times;</span>
                            <img class="modal-content" id="modalImage">
                            <div id="caption" class="caption">Diagnosis of asthma in children</div>
                          </div>
            
                          <table class="note-table">
                              <thead>
                                <tr>
                                    <th colspan="3">Uncommon Features of Asthma</th>
                                </tr>
                                  <tr>
                                        <th></th>
                                      <th>Clinical Clues</th>
                                      <th>Possible Diagnoses</th>
                                  </tr>
                              </thead>
                              <tbody>
                                  <tr>
                                      <td><strong>Perinatal & Family Hx</strong></td>
                                      <td>
                                          <ul>
                                              <li>Symptoms present from birth or perinatal lung problem</li>
                                              <li>Family Hx of unusual chest disease</li>
                                              <li>Severe Upper Respiratory Tract Disease</li>
                                          </ul>
                                      </td>
                                      <td>
                                          <ul>
                                              <li>Developmental anomaly, ciliary dyskinesia, chronic lung disease, CF</li>
                                              <li>Developmental anomaly, neuromuscular disorder, CF</li>
                                              <li>Host defence defect</li>
                                          </ul>
                                      </td>
                                  </tr>
                                  <tr>
                                      <td><strong>Symptoms & Signs</strong></td>
                                      <td>
                                          <ul>
                                              <li>Excessive vomiting or Possetting</li>
                                              <li>Dysphagia</li>
                                              <li>Abnormal voice or cry</li>
                                              <li>Focal chest signs</li>
                                              <li>Inspiratory stridor as well as wheeze</li>
                                              <li>Failure to thrive</li>
                                          </ul>
                                      </td>
                                      <td>
                                          <ul>
                                              <li>Reflux/GERD, Aspiration syndromes</li>
                                              <li>Swallowing problems +/- aspiration</li>
                                              <li>Laryngeal problems</li>
                                              <li>TB, Bronchiectasis, developmental disorder, Post-viral syndrome</li>
                                              <li>Central airway or laryngeal disorder</li>
                                              <li>Host defence, GERD, CF</li>
                                          </ul>
                                      </td>
                                  </tr>
                                  <tr>
                                      <td><strong>Investigations</strong></td>
                                      <td>
                                          <ul>
                                              <li>Focal or Persistent radiological signs</li>
                                          </ul>
                                      </td>
                                      <td>
                                          <ul>
                                              <li>TB, Bronchiectasis, FB aspiration, Developmental disorder, Post-infective disorder, recurrent aspiration</li>
                                          </ul>
                                      </td>
                                  </tr>
                              </tbody>
                          </table>
                          

                          <section id='heading-6-1'>
                            <header>
                              <h3>
                                <a aria-hidden href='#heading-6-1'>History Taking in a Child with Bronchial Asthma</a>
                              </h3>
                            </header>
                            <div class='body'>
                                <p>When taking a history of a child with bronchial asthma, it's important to ask questions that will help you understand the severity, triggers, and management of the condition. Here‚Äôs a guide on the important questions to ask:</p>
                                
                                <h4>1. Symptom History</h4>
                                <ul>
                                  <li><strong>Onset:</strong> When did the symptoms first start? Was there a particular event or trigger?</li>
                                  <li><strong>Nature of Symptoms:</strong> What are the primary symptoms (e.g., wheezing, coughing, shortness of breath, chest tightness)?</li>
                                  <li><strong>Frequency:</strong> How often do these symptoms occur? Are they daily, weekly, or less frequent?</li>
                                  <li><strong>Timing:</strong> Are the symptoms worse at night, early morning, or during certain seasons?</li>
                                  <li><strong>Duration:</strong> How long do the symptoms last when they occur?</li>
                                  <li><strong>Severity:</strong> How severe are the symptoms? Do they interfere with daily activities or sleep?</li>
                                  <li><strong>Associated Symptoms:</strong> Is there any sputum production? If so, what is its color and consistency?</li>
                                </ul>
                                
                                <h4>2. Trigger Factors</h4>
                                <ul>
                                  <li><strong>Environmental:</strong> Are there known triggers like dust, pollen, cold air, smoke, or strong odors?</li>
                                  <li><strong>Allergies:</strong> Is there a history of allergies? Any known triggers such as animals, food, or medications?</li>
                                  <li><strong>Infections:</strong> Have viral infections been associated with the onset of symptoms?</li>
                                  <li><strong>Exercise:</strong> Does physical activity trigger symptoms? What type of exercise?</li>
                                  <li><strong>Weather Changes:</strong> Are symptoms worse with changes in weather, particularly with cold air or humidity?</li>
                                  <li><strong>Emotional Stress:</strong> Do emotional stressors appear to exacerbate symptoms?</li>
                                </ul>
                                
                                <h4>3. Past Medical History</h4>
                                <ul>
                                  <li><strong>Previous Diagnoses:</strong> Has the child been previously diagnosed with asthma or any other respiratory conditions?</li>
                                  <li><strong>Hospitalizations:</strong> Has the child ever been hospitalized for asthma? How many times, and what were the circumstances?</li>
                                  <li><strong>Medication Use:</strong> What medications have been prescribed in the past? Were they effective? Any side effects?</li>
                                  <li><strong>Allergies:</strong> Does the child have a history of eczema, allergic rhinitis, or other atopic conditions?</li>
                                  <li><strong>Growth and Development:</strong> Has asthma affected the child‚Äôs growth or physical development?</li>
                                </ul>
                                
                                <h4>4. Family History</h4>
                                <ul>
                                  <li><strong>Asthma and Allergies:</strong> Is there a family history of asthma, allergies, or other respiratory conditions?</li>
                                  <li><strong>Genetic Predispositions:</strong> Any known genetic conditions related to asthma or respiratory health?</li>
                                </ul>
                                
                                <h4>5. Social and Environmental History</h4>
                                <ul>
                                  <li><strong>Living Conditions:</strong> Where does the child live? Are there any environmental factors at home (e.g., mold, pets, smoke)?</li>
                                  <li><strong>School Environment:</strong> Are there known triggers at school, such as dust or exposure to infections?</li>
                                  <li><strong>Exposure to Smoke:</strong> Is the child exposed to cigarette smoke? Either at home or elsewhere?</li>
                                  <li><strong>Socioeconomic Factors:</strong> Are there any socioeconomic factors that might impact the management of the child‚Äôs asthma?</li>
                                </ul>
                                
                                <h4>6. Impact on Daily Life</h4>
                                <ul>
                                  <li><strong>School Attendance:</strong> Has asthma affected the child‚Äôs school attendance or performance?</li>
                                  <li><strong>Physical Activity:</strong> Does asthma limit the child‚Äôs ability to engage in physical activities?</li>
                                  <li><strong>Quality of Life:</strong> How does asthma affect the child‚Äôs overall quality of life, including sleep and social interactions?</li>
                                </ul>
                                
                                <h4>7. Current Management</h4>
                                <ul>
                                  <li><strong>Medications:</strong> What medications is the child currently using? Include dosages, frequency, and method of administration.</li>
                                  <li><strong>Compliance:</strong> Is the child compliant with their medication regimen? Are there any barriers to compliance?</li>
                                  <li><strong>Use of Rescue Medications:</strong> How often is the rescue inhaler used? Does it effectively relieve symptoms?</li>
                                  <li><strong>Asthma Action Plan:</strong> Does the child have an asthma action plan? Are they and their caregivers familiar with it?</li>
                                </ul>
                                
                                <h4>8. Review of Systems</h4>
                                <ul>
                                  <li><strong>Respiratory:</strong> Ask about any chronic cough, recurrent chest infections, or other respiratory symptoms.</li>
                                  <li><strong>Cardiovascular:</strong> Check for any associated chest pain or palpitations.</li>
                                  <li><strong>Gastrointestinal:</strong> Any history of acid reflux, which can exacerbate asthma symptoms.</li>
                                  <li><strong>Neurological/Psychological:</strong> Assess for any anxiety or stress-related symptoms that could impact asthma control.</li>
                                </ul>
                                
                
                            </div>
                          </section>

                          <section id='heading-6-2'>
                            <header>
                              <h3>
                                <a aria-hidden href='#heading-6-2'>Clinical Examination of a Child with Bronchial Asthma</a>
                              </h3>
                            </header>
                            <div class='body'>
                                <h4>1. General Appearance</h4>
                                <ul>
                                  <li><strong>Distress Level:</strong> Look for signs of respiratory distress such as anxiety, restlessness, or difficulty speaking in full sentences.</li>
                                  <li><strong>Posture:</strong> Note if the child is in a tripod position (leaning forward with hands on knees), which is often seen in severe respiratory distress.</li>
                                  <li><strong>Cyanosis:</strong> Check for cyanosis (bluish discoloration of the lips or nail beds), indicating hypoxia.</li>
                                </ul>
                                
                                <h4>2. Respiratory Rate and Effort</h4>
                                <ul>
                                  <li><strong>Tachypnea:</strong> Measure the respiratory rate. An increased rate (tachypnea) may indicate distress.</li>
                                  <li><strong>Use of Accessory Muscles:</strong> Observe for the use of accessory muscles of respiration (neck and intercostal muscles), which can signify increased work of breathing.</li>
                                  <li><strong>Nasal Flaring and Grunting:</strong> In younger children, nasal flaring and grunting are signs of severe respiratory effort.</li>
                                  <li><strong>Wheezing:</strong> Listen for wheezing, which is a high-pitched sound typically heard during expiration. Wheezing may also be present during inspiration in more severe cases.</li>
                                </ul>
                                
                                <h4>3. Chest Examination</h4>
                                <ul>
                                  <li><strong>Inspection:</strong>
                                    <ul>
                                      <li><strong>Chest Shape:</strong> Look for any signs of hyperinflation (barrel chest), which can occur in chronic or severe asthma.</li>
                                      <li><strong>Symmetry:</strong> Assess for symmetrical chest movement during breathing.</li>
                                    </ul>
                                  </li>
                                  <li><strong>Palpation:</strong>
                                    <ul>
                                      <li><strong>Tenderness:</strong> Check for any tenderness or deformities.</li>
                                      <li><strong>Tactile Fremitus:</strong> This can be reduced in areas of hyperinflation.</li>
                                    </ul>
                                  </li>
                                  <li><strong>Percussion:</strong>
                                    <ul>
                                      <li><strong>Hyperresonance:</strong> Percuss the chest to check for hyperresonance, which may indicate air trapping.</li>
                                    </ul>
                                  </li>
                                  <li><strong>Auscultation:</strong>
                                    <ul>
                                      <li><strong>Breath Sounds:</strong> Assess the breath sounds. Reduced breath sounds may indicate severe obstruction or air trapping.</li>
                                      <li><strong>Wheezes:</strong> Identify the presence, timing (inspiratory vs. expiratory), and location of wheezes.</li>
                                      <li><strong>Prolonged Expiration:</strong> A prolonged expiratory phase is typical in asthma.</li>
                                      <li><strong>Rhonchi:</strong> Coarse, low-pitched wheezing (rhonchi) may indicate mucus in the larger airways.</li>
                                      <li><strong>Silent Chest:</strong> A very concerning sign, a "silent chest" occurs when wheezing stops due to severe obstruction, indicating a life-threatening situation.</li>
                                    </ul>
                                  </li>
                                </ul>
                                
                                <h4>4. Cardiovascular Examination</h4>
                                <ul>
                                  <li><strong>Heart Rate:</strong> Assess for tachycardia, which can be a sign of hypoxia or a side effect of bronchodilators.</li>
                                  <li><strong>Pulsus Paradoxus:</strong> Measure the blood pressure for pulsus paradoxus, where there is a greater than normal drop in systolic pressure during inspiration. This can indicate severe asthma.</li>
                                  <li><strong>Peripheral Perfusion:</strong> Check capillary refill time and peripheral pulses to assess perfusion.</li>
                                </ul>
                                
                                <h4>5. ENT Examination</h4>
                                <ul>
                                  <li><strong>Nasal Polyps:</strong> Inspect the nasal passages for polyps, which can be associated with allergic conditions.</li>
                                  <li><strong>Nasal Mucosa:</strong> Look for signs of allergic rhinitis, such as swollen, pale, or bluish nasal mucosa.</li>
                                  <li><strong>Oropharynx:</strong> Assess for throat erythema or postnasal drip, which may indicate allergic rhinitis or sinusitis.</li>
                                </ul>
                                
                                <h4>6. Skin Examination</h4>
                                <ul>
                                  <li><strong>Eczema:</strong> Look for signs of atopic dermatitis (eczema), which is commonly associated with asthma.</li>
                                  <li><strong>Allergic Shiners:</strong> Check for dark circles under the eyes, which can be a sign of chronic allergic conditions.</li>
                                  <li><strong>Dermatographism:</strong> Gently scratch the skin to see if it becomes raised and red, which is another sign of atopy.</li>
                                </ul>
                                
                                <h4>7. Abdominal Examination</h4>
                                <ul>
                                  <li><strong>Diaphragmatic Excursion:</strong> Assess for any signs of abdominal distension, which can limit diaphragmatic movement and worsen respiratory symptoms.</li>
                                  <li><strong>Hepatomegaly:</strong> In severe asthma, air trapping can push the diaphragm downward, leading to a palpable liver edge.</li>
                                </ul>
                                
                                <h4>8. Neurological and Mental Status</h4>
                                <ul>
                                  <li><strong>Alertness:</strong> Evaluate the child‚Äôs level of alertness and orientation. Drowsiness or confusion may indicate severe hypoxia.</li>
                                  <li><strong>Speech:</strong> Check for the ability to speak in full sentences. Difficulty speaking in complete sentences can be a sign of severe respiratory distress.</li>
                                </ul>
                                
                
                            </div>
                          </section>
        </div>
      </section>

      <section id='header-7'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-7'> Conditions Often Confused with Asthma</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
                <li>Bronchiolitis</li>
                <li>Pulmonary Tuberculosis</li>
                <li>Aspiration of Foreign Body (FB)</li>
                <li>Hyperventilation Syndrome</li>
                <li>Vocal Cord Dysfunction Syndrome</li>
                <li>Habit Cough</li>
                <li>Bronchiectasis</li>
                <li>Ciliary Dyskinesia</li>
                <li>Alpha-1 Antitrypsin Deficiency</li>
                <li>Cystic Fibrosis in Caucasians</li>
                <li>Hysteria (especially in adolescent girls with prior wheezy illnesses)</li>
            </ul>
            
        </div>
      </section>

      <section id='header-8'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-8'>Comorbidities & Complications </a>
          </h2>
        </header>
        <div class='body'>

            <h4>Co-morbidities:</h4>
            <ul>
                <li>Allergic rhinoconjunctivitis</li>
                <li>Atopic eczema</li>
                <li>Vernal conjunctivitis</li>
                <li>Food allergy</li>
                <li>Drug hypersensitivity</li>
                <li>*<strong>Menses & Pregnancy</strong></li>
                <li>*<strong>Gastroesophageal Reflux Disease (GERD)</strong></li>
                <li>*<strong>Chronic (bacterial) sinusitis</strong></li>
                <li>*<strong>Allergic Bronchopulmonary Aspergillosis (ABPA)</strong></li>
            </ul>
            <p><strong>*Can worsen disease severity/frequency</strong></p>
            
            <h4>Complications</h4>
            <ul>
                <li><strong>Respiratory</strong></li>
                <ul>
                    <li>Air-leak syndromes</li>
                    <li>Atelectasis</li>
                    <li>Respiratory failure</li>
                    <li>Ventilation-perfusion mismatch</li>
                    <li>Mucoid impaction of the bronchi</li>
                    <li>Right middle lobe syndrome</li>
                </ul>
                <li><strong>Non-respiratory</strong></li>
                <ul>
                    <li>Growth aberrations vis-√†-vis effects of corticosteroids; possible prepubertal deceleration with delayed onset of puberty</li>
                    <li>Sleep disorders</li>
                    <li>Sudden symmetric limb paralysis (Hopkins syndrome)</li>
                    <li>Acid-base aberrations</li>
                    <li><strong>Note:</strong> Like in bronchiolitis, heart failure is rare, but cor pulmonale may occur.</li>
                </ul>
            </ul>
            
        </div>
      </section>

      <section id='header-9'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-9'>Non-PFT Ancillary/Laboratory Investigations </a>
          </h2>
        </header>
        <div class='body'>

            <h4>Chest Radiograph</h4>
            <ul>
                <li>Usually indicated in a child with the first episode of wheeze, cough, and/or chest tightness to exclude alternative diagnoses, such as foreign body (FB).</li>
                <li>Normal or exaggerated bronchovascular markings may be observed between episodes of acute attacks.</li>
                <li>Increased anteroposterior (AP) diameter, flattened diaphragmatic domes, horizontal ribs, and relative microcardia may suggest hyperinflation during an acute attack.</li>
                <li>Associated radiologic signs of right middle lobe (RML) syndrome due to mucus plug obstruction may be evident, but co-existing pneumonia is an unusual feature of acute asthma.</li>
            </ul>
            
            <h4>Skin Prick Test</h4>
            <ul>
                <li>Drops of allergen solution are placed on the skin.</li>
                <li>The point of a disposable needle, held almost parallel to the skin, is used to introduce the solution into the superficial epidermis.</li>
                <li>A new needle is used for each allergen solution.</li>
                <li>The reaction is read in 20 minutes.</li>
                <li>The diameter of the urticaria (not erythema!) is measured; a value greater than 2 mm is considered a positive reaction.</li>
            </ul>
            

        </div>
      </section>


      <section id='header-10'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-10'>Classification </a>
          </h2>
        </header>
        <div class='body'>
            <ul>
                <li><strong>Traditional</strong>
                    <ul>
                        <li>Intrinsic or cryptogenic</li>
                        <li>Extrinsic</li>
                    </ul>
                </li>
                <li><strong>Based on phenotype</strong>
                    <ul>
                        <li>Transient Early Wheezers (TEW)</li>
                        <li>Atopic</li>
                        <li>Non-atopic</li>
                    </ul>
                </li>
                <li><strong>Based on severity</strong>
                    <ul>
                        <li>Mild intermittent</li>
                        <li>Mild persistent (Chronic)</li>
                        <li>Moderate persistent (Chronic)</li>
                        <li>Severe persistent (Chronic)</li>
                    </ul>
                </li>
            </ul>
            
            <h4>Traditional Classification Based on Triggering/Precipitating Factors</h4>
            <ul>
                <li><strong>Intrinsic</strong> ‚Äì Non-atopic, asthmatics react to internal, nonallergenic factors</li>
                <li><strong>Extrinsic</strong> ‚Äì Patients sensitive to external allergens</li>
            </ul>
            

            <table class="note-table">
                <thead>
                    <tr>
                        <th colspan="2">Intrinsic vs Extrinsic Triggers</th>
                    </tr>
                    <tr>
                        <th>Intrinsic</th>
                        <th>Extrinsic</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Acute Respiratory infections (esp. < 6 yrs)</td>
                        <td>Smoke</td>
                    </tr>
                    <tr>
                        <td>Emotional Stress</td>
                        <td>Pollen</td>
                    </tr>
                    <tr>
                        <td>Exercise & Fatigue</td>
                        <td>Animal Dander</td>
                    </tr>
                    <tr>
                        <td>Endocrine Changes</td>
                        <td>House dust mites (D. pteronyssinus and D. farinae)</td>
                    </tr>
                    <tr>
                        <td>Weather ‚Äì extreme ‚Äì cold/hot</td>
                        <td>Cockroaches'</td>
                    </tr>
                    <tr>
                        <td>Humidity Variations</td>
                        <td>House Dust Or Mold</td>
                    </tr>
                    <tr>
                        <td>Anxiety</td>
                        <td>Kapok Or Feather Pillows</td>
                    </tr>
                    <tr>
                        <td>Coughing Or Laughing</td>
                        <td>Food Additives Containing Sulfites</td>
                    </tr>
                    <tr>
                        <td>Genetic Factors</td>
                        <td>Other Sensitizing substances; e.g. Fried oil, insecticide, perfume</td>
                    </tr>
                    <tr>
                        <td>Drugs; e.g. aspirin, Œ≤-blockers</td>
                        <td></td>
                    </tr>
                </tbody>
            </table>
            

            <br>

            <table class="note-table">
                <thead>
                    <tr>
                        <th colspan="5">Classification of Asthma Severity</th>
                    </tr>
                    <tr>
                        <th>Severity</th>
                        <th>Symptoms Per Day</th>
                        <th>Symptoms Per Night</th>
                        <th>PEF or FEV1</th>
                        <th>PEF Variability</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Intermittent</td>
                        <td>&lt; 1 time a week</td>
                        <td>&#8804; 2 times a month</td>
                        <td>&#8805; 80%</td>
                        <td>&lt; 20%</td>
                    </tr>
                    <tr>
                        <td>Mild Persistent</td>
                        <td>&gt; 1 time a week but &lt; 1 time a day</td>
                        <td>&gt; 2 times a month</td>
                        <td>&#8805; 80%</td>
                        <td>20 ‚Äì 30%</td>
                    </tr>
                    <tr>
                        <td>Moderate Persistent</td>
                        <td>Daily</td>
                        <td>Attacks affect activity</td>
                        <td>60% - 80%</td>
                        <td>&gt; 30%</td>
                    </tr>
                    <tr>
                        <td>Severe Persistent</td>
                        <td>Continuous</td>
                        <td>Frequent</td>
                        <td>&#8804; 60%</td>
                        <td>&gt; 30%</td>
                    </tr>
                </tbody>
            </table>
            
        </div>
      </section>


      <section id='header-11'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-11'>Management Strategies </a>
          </h2>
        </header>
        <div class='body'>

            <section id='heading-11-1'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-11-1'>Goals</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                        <li>Achieving and maintaining symptom control & preventing exacerbations by attaining normal or near-normal lung functions.</li>
                        <li>Optimize lifestyles by maintaining normal activity levels including exercise & ensuring no loss of school days.</li>
                        <li>Avoiding adverse effects of anti-asthma medications by opting for treatments with the lowest side-effect profiles.</li>
                    </ul>
                    
                    <h4>GINA 6-Part Management Programme</h4>
                    <ul>
                        <li><strong>Co-management or Guided Self Management</strong>, i.e., Parent/patient education regarding partnership in asthma.</li>
                        <li><strong>Assessing & Monitoring Severity</strong> with objective measures of lung function.</li>
                        <li><strong>Avoiding &/or Controlling Trigger Factors</strong>, i.e., Environmental manipulation.</li>
                        <li><strong>Establishing Medication Plans for Chronic Management</strong>, i.e., Day-to-day management guidelines.</li>
                        <li><strong>Establishing Plans for Managing Acute Exacerbations</strong>.</li>
                        <li><strong>Providing Regular Follow-up Care</strong>.</li>
                    </ul>
                    
                    <h4>Co-management or Guided Self Management</h4>
                    <p>Accomplished via:</p>
                    <ul>
                        <li>Effective & open communication & encouragement for achieving patient/parent motivation, skill, & confidence.</li>
                        <li>Making the child/parent an effective first line of accomplishing management strategies for controlling asthma-related symptoms.</li>
                        <li>Giving clear guidelines on when medical/hospital intervention is required, i.e., a written action plan.</li>
                    </ul>
                    
                    <p>Remember the 4 (or 5) Rs of Co-management:</p>
                    <ul>
                        <li>Reaching an agreement on goals like sports‚Äô participation, avoiding frequent exacerbations/night-time symptoms, school absence, & side effects of anti-asthma medications.</li>
                        <li>Rehearsal.</li>
                        <li>Repetition.</li>
                        <li>Reward/reinforcement.</li>
                        <li>Providing written guidelines & action plan for easy reference.</li>
                    </ul>
                    
                    <h4>Four (4) Elements of an Effective Co-management Programme</h4>
                    <ul>
                        <li>Ensuring patient/parents‚Äô proper understanding of the condition.</li>
                        <li>Monitoring symptoms via the use of home-usable devices, especially PF meter, symptom diary & drug use/compliance.</li>
                        <li>Providing a pre-arranged action plan for day-to-day care and acute exacerbations.</li>
                        <li>Provision of written guidelines.</li>
                        <li>Above all, interaction between the family and the physician constitutes the most important prerequisite for addressing complex psychosocial factors like poor self-esteem, denial, and poor medication compliance, which are likely to impede effective control.</li>
                    </ul>
                    
                    <h4>British Guideline on Self Management (2007)</h4>
                    <p>‚ÄúPatients with asthma should have an agreed written action plan & their own peak flow meter with regular checks of inhaler technique & compliance. They should know when to increase their medications and when to seek medical assistance. Use of asthma action plans has been shown to decrease hospitalizations and deaths due to asthma.‚Äù</p>
                    
        
                    <h4>Objective Measures of Assessing & Monitoring Severity via Measuring Lung Function</h4>
                    <p>Accomplished via:</p>
                    <ul>
                        <li>Appropriate/effective home use of peak flow meters; every patient should own a PEF meter.</li>
                        <li>Effective use of a symptom diary as a guide to the need and type of medications required using the action plan guidelines.</li>
                        <li>Intermittent measurement of PFTs using spirometry & documenting hard copies of flow volume curves.</li>
                    </ul>
                    
                    <h4>Avoiding &/or Controlling Trigger Factors</h4>
                    <p>Accomplished via:</p>
                    <ul>
                        <li>Control or elimination of biotic or abiotic potential or proven allergens/provocateurs via HDM avoidance measures, removal of household pets & avoiding exposure to cigarette smoke.</li>
                        <li>Pharmacologic control of allergen exposure-related airway inflammation via the use of safe (usually inhaled) anti-inflammatory agents.</li>
                        <li>Immunotherapy or desensitization.</li>
                    </ul>
                    
                    <h4>Does Reducing Asthma Triggers Always Work?</h4>
                    <p>The control of allergens has not been demonstrated to work as monotherapy. A recent study showed that house dust mite allergen avoidance and dietary fatty acid modification in the first few years of life do not prevent asthma, eczema, or atopy in children with a family history of asthma (Guy et al, Allergy, 2006).</p>
                    <p>Conventional wisdom and indeed the recommendations from many asthma experts still endorse allergen avoidance measures in early life.</p>
                    
                    <h4>Early Interventions Don't Prevent Asthma in High-Risk Children</h4>
                    <p>House dust mite allergen (HDM) avoidance and dietary fatty acid modification in the first few years of life do not prevent asthma, eczema, or atopy in children with a family history of asthma, new research shows.</p>
                    <p>Sensitization to HDM and consumption of diets with a low omega-3 to -6 fatty acid ratio have been linked to asthma. Guy et al studied 616 children who were randomized to receive HDM avoidance, a diet with an increased omega-3 to -6 fatty acid ratio, both interventions, or no intervention during the first 5 years of life. Of these children, 516 were available for evaluation at 5 years.</p>
                    <p>The HDM avoidance measure involved the use of allergen-impermeable linens and regular washing with an anti-HDM detergent. With the diet intervention, parents were encouraged to prepare their child's meals using canola-based oils and tuna oil capsules to achieve a high omega-3 to -6 fatty acid ratio.</p>
                    <p>Although HDM avoidance measure reduced bedding allergen levels by 61%, it had no effect on the occurrence of asthma, wheeze, or atopy. In fact, eczema was actually more common in the HDM avoidance group than in controls: 26% vs. 19%.</p>
                    <p>Similarly, while the diet intervention did succeed in increasing the omega-3 to -6 fatty acid ratio, it did not prevent asthma, wheezing, eczema, or atopy.</p>
                    <p>Despite the null findings of the present study, previous reports support the view that, under certain circumstances, asthma can be prevented. However, the most effective, practical forms of early life environmental modification and the circumstances under which it will be appropriate to implement them remain to be established.</p>
    
                </div>
              </section>

              <section id='heading-11-2'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-11-2'>Newer Therapy of Chronic Asthma</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                        <li>Omalizumab</li>
                        <li>Sublingual Immunotherapy</li>
        
                        <h4>Omalizumab</h4>
                        <p>Omalizumab is a recombinant DNA-derived humanized IgG monoclonal antibody that selectively binds to human immunoglobulin E (IgE). It inhibits the binding of IgE to the high-affinity IgE receptor on the surface of mast cells and basophils, limiting the release of allergic mediators.</p>
                        <p>Omalizumab is approved for use in children 6 years and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.</p>
                        
                        <h4>Sublingual Immunotherapy</h4>
                        <p>Sublingual immunotherapy is a newer, more convenient option than injectable immunotherapy.</p>
                    </ul>
                    
    
                </div>
              </section>

              <section id='heading-11-3'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-11-3'>Medication Plans for Chronic Management</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                        <li>Accomplished via:</li>
                        <ul>
                            <li>Valid classification of the disease severity using clinical & PFT parameters as appropriate (refer to classification criteria into 4 clinical categories).</li>
                            <li>Appending the appropriate medications for the level of severity and subsequently stepping up or down the medications depending on the frequency & severity of symptoms, and objective measures of PFTs/PEFR values, i.e., stepwise approach.</li>
                            <li>Note the current emphasis on the need for an early introduction of effective inhaled anti-inflammatory medications for long-term control, and the related need for demonstrating & ascertaining proficiency in the use of inhaler devices, as well as the use of rescue treatment with systemic steroids for acute attacks.</li>
                        </ul>
                    
                        <h4>Classification for Long-Term Management</h4>
                        <ul>
                            <li>Intermittent</li>
                            <li>Mild persistent</li>
                            <li>Moderate persistent</li>
                            <li>Severe persistent</li>
                        </ul>
                    
        
                                    <!-- image here -->
                    <div class="image-container">
                        <img src="../figures/childhood-bronchial-asthma (6).jpg" alt="" onclick="openModal(this)">
                        <div class="caption">Summary of stepwise management in children less than 5</div>
                      </div>
                      
                      <div id="myModal" class="modal">
                        <span class="close" onclick="closeModal()">&times;</span>
                        <img class="modal-content" id="modalImage">
                        <div id="caption" class="caption">Summary of stepwise management in children less than 5</div>
                      </div>
        
                                  <!-- image here -->
                    <div class="image-container">
                        <img src="../figures/childhood-bronchial-asthma (7).jpg" alt="" onclick="openModal(this)">
                        <div class="caption">Summary of stepwise management in children 5-12</div>
                      </div>
                      
                      <div id="myModal" class="modal">
                        <span class="close" onclick="closeModal()">&times;</span>
                        <img class="modal-content" id="modalImage">
                        <div id="caption" class="caption">Summary of stepwise management in children 5-12</div>
                      </div>
        
                                  <!-- image here -->
                    <div class="image-container">
                        <img src="../figures/childhood-bronchial-asthma (8).jpg" alt="" onclick="openModal(this)">
                        <div class="caption">Pharmacological management</div>
                      </div>
                      
                      <div id="myModal" class="modal">
                        <span class="close" onclick="closeModal()">&times;</span>
                        <img class="modal-content" id="modalImage">
                        <div id="caption" class="caption">Pharmacological management</div>
                      </div>
                        
        
                      <h4>Immunotherapy</h4>
                      <ul>
                          <li>Immunotherapy can be used as an adjunct to standard drug therapy in allergic asthmatic children.</li>
                          <li>Sublingual (allergy drops) and injectable (allergy shots) therapies have been shown to reduce the presence of asthma and the overall use of asthma medication.</li>
                      </ul>
    
                </div>
              </section>

              <section id='heading-11-4'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-11-4'>Management of Acute Exacerbations</a>
                  </h3>
                </header>
                <div class='body'>
                    <h4>Establishing Plans for </h4>
                    <ul>
                        <li>Acute attacks are markers of failure of chronic/day-to-day management (by physician and family/patient), or massive exposure to potential trigger(s).</li>
                        <li>Note the emphasis on the use of inhaled bronchodilators for acute exacerbations as opposed to systemic steroids (parenteral or oral), which are more valuable for managing chronic inflammation rather than acute flares.</li>
                        
                    </ul>
                    
      
                                <!-- image here -->
                  <div class="image-container">
                      <img src="../figures/childhood-bronchial-asthma (6).png" alt="" onclick="openModal(this)">
                      <div class="caption">Summary of acute asthmatic response</div>
                    </div>
                    
                    <div id="myModal" class="modal">
                      <span class="close" onclick="closeModal()">&times;</span>
                      <img class="modal-content" id="modalImage">
                      <div id="caption" class="caption">Summary of acute asthmatic response</div>
                    </div>
      
      
                                <!-- image here -->
                  <div class="image-container">
                      <img src="../figures/childhood-bronchial-asthma (9).jpg" alt="" onclick="openModal(this)">
                      <div class="caption">Levels of severity of acute exacerbation of asthma</div>
                    </div>
                    
                    <div id="myModal" class="modal">
                      <span class="close" onclick="closeModal()">&times;</span>
                      <img class="modal-content" id="modalImage">
                      <div id="caption" class="caption">Levels of severity of acute exacerbation of asthma</div>
                    </div>
      
                                <!-- image here -->
                  <div class="image-container">
                      <img src="../figures/childhood-bronchial-asthma (10).jpg" alt="" onclick="openModal(this)">
                      <div class="caption">Clinical features for assessment of severity</div>
                    </div>
                    
                    <div id="myModal" class="modal">
                      <span class="close" onclick="closeModal()">&times;</span>
                      <img class="modal-content" id="modalImage">
                      <div id="caption" class="caption">Clinical features for assessment of severity</div>
                    </div>
      
      
                                <!-- image here -->
                  <div class="image-container">
                      <img src="../figures/childhood-bronchial-asthma (11).jpg" alt="" onclick="openModal(this)">
                      <div class="caption">Management of asthma in children in A and E</div>
                    </div>
                    
                    <div id="myModal" class="modal">
                      <span class="close" onclick="closeModal()">&times;</span>
                      <img class="modal-content" id="modalImage">
                      <div id="caption" class="caption">Management of asthma in children in A and E</div>
                    </div>
    
                </div>
              </section>

         



              <section id='heading-11-5'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-11-5'>Drugs Available for Treatment of Asthma</a>
                  </h3>
                </header>
                <div class='body'>

                    <h4>1. Relievers (usually blue)</h4>
                    <ul>
                        <li>Œ≤2 agonists: salbutamol, albuterol, terbutaline</li>
                        <li>Adrenaline</li>
                        <li>Theophyllines</li>
                        <li>Anticholinergics</li>
                        <li>Ephedrine-containing drugs (e.g., franol, tedral) are of little relevance in modern practice</li>
                    </ul>
                    
                    <h4>2. Preventers (usually beige or brown)</h4>
                    <ul>
                        <li>Sodium cromoglycate</li>
                        <li>Ketotifen</li>
                        <li>Nedocromil sodium</li>
                        <li>Corticosteroids (CCS)</li>
                        <ul>
                            <li>Inhaled corticosteroids (ICS): budesonide, beclomethasone, fluticasone</li>
                            <li>Therapeutic importance more evident in the past 2 or more decades due to the greater availability of these considerably safer inhaled preparations</li>
                            <li>Probably the most effective preventer of frequent exacerbations</li>
                            <li>Systemic steroids: prednisolone (short-term rescue treatment for acute exacerbations, 5-7 days); hydrocortisone (useful in the management of severe acute asthma)</li>
                            <li>In 1980, Clark remarked:
                                <blockquote>
                                    ‚ÄòIn general, CCS are used when other measures have failed to control asthma‚Äô<br>
                                    ‚ÄòThere remains some doubt about the role of CCS in the management of acute severe asthma.‚Äô<br>
                                    Clark TJH, 1980
                                </blockquote>
                            </li>
                        </ul>
                    </ul>
                    
                    <h4>3. Controllers (possibly purple)</h4>
                    <ul>
                        <li>Long-acting beta-2 agonists: salmeterol, formoterol, bambuterol</li>
                        <li>Useful for long-term control as add-on agents for frequent nocturnal symptoms</li>
                    </ul>
                    


                    <table class="note-table">
                      <thead>
                        <tr>
                            <th colspan="3">Classification of Drugs Used in the Treatment of Asthma</th>
                        </tr>
                        <tr>
                          <th>PREVENTERS<br><small>(Anti-inflammatory action to prevent asthma attacks)</small></th>
                          <th>CONTROLLERS<br><small>(Sustained bronchodilator action but weak or unproven anti-inflammatory action)</small></th>
                          <th>RELIEVERS<br><small>(Quick relief of symptoms and for use in acute attacks as PRN dosage only)</small></th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td>
                            <ul>
                              <li>Inhaled corticosteroids</li>
                              <ul>
                                <li>Beclomethasone</li>
                                <li>Budesonide</li>
                                <li>Fluticasone</li>
                                <li>Flunisolide</li>
                                <li>Triamcinolone</li>
                              </ul>
                              <li>Oral corticosteroids</li>
                              <ul>
                                <li>Prednisone</li>
                                <li>Prednisolone</li>
                                <li>Methylprednisolone</li>
                              </ul>
                              <li>Disease modifiers - Leukotriene antagonists</li>
                              <ul>
                                <li>Montelukast</li>
                                <li>Zafirlukast</li>
                              </ul>
                            </ul>
                          </td>
                          <td>
                            <ul>
                              <li>Long-acting Œ≤2 agonists</li>
                              <ul>
                                <li>Salmeterol</li>
                                <li>Formoterol</li>
                              </ul>
                              <li>Sustained release theophylline tablets</li>
                            </ul>
                          </td>
                          <td>
                            <ul>
                              <li>Short-acting Œ≤2 agonists</li>
                              <ul>
                                <li>Salbutamol</li>
                                <li>Terbutaline</li>
                                <li>Fenoterol</li>
                              </ul>
                              <li>Anti-cholinergics</li>
                              <li>Short-acting theophyllines</li>
                            </ul>
                          </td>
                        </tr>
                      </tbody>
                    </table>
                    
                    <br>


                    <table class="note-table">
                      <thead>
                        <tr>
                            <th colspan="5">Comparative Effects of Anti-asthma Medications</th>
                        </tr>
                        <tr>
                          <th>Medications</th>
                          <th>Bronchodilator</th>
                          <th>Bronchoprotection:<br>Response to Allergen Exp.</th>
                          <th>Histamine</th>
                          <th>Resolution</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td><strong>Bronchodilators:</strong><br>Œ≤‚Äìadrenergic</td>
                          <td>+++</td>
                          <td>I</td>
                          <td>+++< col/td>
                          <td>-</td>
                        </tr>
                        <tr>
                          <td>Theophylline</td>
                          <td>++</td>
                          <td>I, L</td>
                          <td>+</td>
                          <td>+</td>
                        </tr>
                        <tr>
                          <td>Anticholinergic</td>
                          <td>+</td>
                          <td>-</td>
                          <td>ND</td>
                          <td>ND</td>
                        </tr>
                        <tr>
                          <td><strong>Non-bronchodilator medications:</strong><br>Cromolyn Na</td>
                          <td>_</td>
                          <td>I, L, AR</td>
                          <td>_</td>
                          <td>++</td>
                        </tr>
                        <tr>
                          <td>Nedocromil Na</td>
                          <td>_</td>
                          <td>I, L, AR</td>
                          <td>_</td>
                          <td>+++</td>
                        </tr>
                        <tr>
                          <td>Glucocorticoids</td>
                          <td>I, L, AR</td>
                          <td>L, AR</td>
                          <td>+++</td>
                          <td>+++</td>
                        </tr>
                      </tbody>
                    </table>
                    
                    <p><strong>Note:</strong></p>
                    <ul>
                      <li>I = Immediate response</li>
                      <li>L = Late response</li>
                      <li>AR = Airway hyperresponsiveness</li>
                      <li>ND = Not determined</li>
                    </ul>
                    
                    <h4>ARI, Pathogens & Asthma</h4>

                    <ul>
                      <li><strong>ARI induces Bronchial Hyperresponsiveness (BHR)</strong> in early life.</li>
                      <li>Relationship between snuffles (cold) and acute wheezy illnesses has been recognized for ages, as evident in Milne‚Äôs famous quote:
                        <blockquote>‚ÄúThey asked if the sneezles come after the wheezeles or if the first sneezles came first.‚Äù</blockquote>
                      </li>
                      <li>Freeman & Todd (1962) suggested that asthmatics are predisposed to relative IgA deficiency, which may be associated with atopy.</li>
                      <li>Numerous studies (see table) have shown that it is viral, as against bacterial infection, that induces BHR and subsequently triggers flares of asthma.</li>
                      <li>In a study of about 56 acute asthmatic attacks, Gbadero, Johnson & Aderele (1996, Thorax) identified a viral agent in about 50% of those who had viral studies; RSV, PIVs, and Flu A were the commonest IDs.</li>
                    </ul>
                    
                </div>
              </section>


        </div>
      </section>

      <section id='header-12'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-12'> What's New?</a>
          </h2>
        </header>
        <div class='body'>
            <h4>Any Changes in Asthma Mx or Are We Going Round in Cycles?</h4>

            <p>In the last 25 years:</p>
            <ul>
              <li><strong>Definition of asthma has changed.</strong></li>
              <li><strong>Prevalence of asthma has doubled.</strong></li>
              <li><strong>Better understanding of the pathogenesis and pathophysiology of asthma</strong>, especially the central role of chronic airway inflammation.</li>
              <li><strong>Drug management has improved</strong> with the availability of safer anti-inflammatory agents and much better drug delivery devices.</li>
              <li><strong>Globally applicable guidelines</strong> are now available for the management of asthma with regular reviews.</li>
            </ul>
            
            <h4>Novel Theories on Asthma</h4>
            <ul>
              <li><strong>Gastro-oesophageal reflux disease</strong>: Lowered intra-oesophageal pH initiates a fall in FEV1.</li>
              <li><strong>United airways disease</strong>: Hypothesis implies unity of the upper and lower airways in asthma.</li>
              <li><strong>Hygiene hypothesis</strong>: States that reduced exposure to allergens in early life is implicated in the growing propensity for allergy sensitization.</li>
            </ul>
            
            <h4>Pathophysiology of Asthma ‚Äì The Immune System</h4>
            <ul>
              <li>The 3 main components are <strong>antibodies, inflammatory cells,</strong> and <strong>inflammatory mediators.</strong></li>
              <li>The basis for the immunological response can be found in utero.</li>
              <li>There are <strong>B & T lymphocytes</strong>. B lymphocytes are responsible for the production of immunoglobulins, especially IgE. T helper (Th) lymphocytes include Th1 & Th2.</li>
              <li><strong>Th2</strong> is responsible for the production of cytokines, especially IL-4, which stimulates B cells to produce IgE.</li>
              <li><strong>IgE</strong> is fundamental to the allergic immune response.</li>
              <li><strong>Th1</strong> secretes IFNŒ≥, which is toxic. Its effect is countered by IL-4 & IL-5 produced by Th2.</li>
              <li>It seems that the natural state of the fetus is skewed towards the production of Th2 cells.</li>
            </ul>
            
            <h4>The Unique Paradoxes of Asthma:</h4>
            <ul>
              <li><strong>Reversible, yet potentially fatal.</strong></li>
              <li><strong>Presentation is episodic, yet it is a chronic (inflammatory) disorder.</strong></li>
              <li><strong>There are newer & more specific pharmacologic agents available, yet most deaths are due to under-treatment!</strong></li>
            </ul>
            
        </div>
      </section>





      <hr style="margin: 3rem 0;">

      <!-- PRACTICE QUESTIONS CONTAINER -->

      <div class="custom-card" id="custom-card-2">
        <div class="icon"><img src="../images/icons/practice-questions.png" alt="Icon" class="icon"></div>
        <div class="title"> 
          <h2>Practice Questions</h2>
        </div>
        <div class="line">
          <p>Check how well you grasp the concepts by answering the following questions...</p>
        </div>
        <div class="content">
          <ol>
            <li><i>This content is not available yet.</i></li>
          </ol>
        </div>
        <div class="read-more" onclick="toggleContent('custom-card-2')">Read More üç™</div>
      </div>

      <!-- END OF PRACTICE QUESTIONS CONTAINER -->


      <!-- CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
      <div class="contact">
        <div class="comment-container">
          <div class="comment-icon">
            <!-- Add your icon image here -->
            <img src="../images/icons/comment.png" alt="Comment Icon">
          </div>
          <div class="comment-text">
            <!-- Add your text here -->
            <p>Send your comments, corrections, explanations/clarifications and requests/suggestions </p>
          </div>
          <a href="https://docs.google.com/forms/d/e/1FAIpQLSdx2teDCmW6ivSeKLQg7zF_jy7Yfg_1Gqm84_UT0PQPATsNug/viewform?usp=sf_link" class="comment-button">
            here
            <!-- <img src="../images/icons/whatsapp.png" alt="Image Icon"> -->
          </a>
        </div>

        <div class="contributors-container">

          <h2 class="contributors-header">Contributors</h2>
  
        <br>
            <div class="contributor-box">
                <img class="contributor-avatar" src="../images/icons/woman.png" alt="Contributor 1 Avatar">
                <div class="contributor-info">
                    <h3 class="contributor-name">Jane Smith</h3>
                    <p class="contributor-description">She is not a real contributor.</p>
                    <div class="social-links">
                        <a href="#" target="_blank" class="social-icon">
                            <img src="../images/icons/whatsapp.png" alt="Social Icon 1">
                        </a>
                        <a href="#" target="_blank" class="social-icon">
                            <img src="../images/icons/twitter.png" alt="Social Icon 2">
                        </a>
                    </div>
                </div>
            </div>
        
            <div class="contributor-box">
                <img class="contributor-avatar" src="../images/icons/man.png" alt="Contributor 2 Avatar">
                <div class="contributor-info">
                    <h3 class="contributor-name">John Doe</h3>
                    <p class="contributor-description">He is not a real contributor.</p>
                    <div class="social-links">
                      <a href="#" target="_blank" class="social-icon">
                        <img src="../images/icons/whatsapp.png" alt="Social Icon 1">
                    </a>
                    <a href="#" target="_blank" class="social-icon">
                        <img src="../images/icons/linkedin.png" alt="Social Icon 2">
                    </a>
                    </div>
                </div>
            </div>
        
        </div>
      </div>

            <!-- END OF CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p id="popup-trigger">disclaimer</p>

          <!-- The pop-up dive content -->
          <div id="popup" class="popup">
            <p>The contents on this ‚Äòwebsite‚Äô are for educational purposes only. The creators and operators of this website make no warranties, express or implied, regarding the accuracy, currency, or completeness of the information provided on the website. They shall not be held responsible for any errors or omissions, or for any actions taken based on the information provided on this website.</p>
            <button class="popup-close" onclick="closePopup()">Close</button>
          </div>    
          <p><a href="../about-temp2.html">about</a> </p>   
          <p><a href="../contribute.html">contribute</a> </p>
        </div>

        <div class="footer-beta">
          <p>thisisatestversion</p>
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="../main.js"></script>
<script src="../modal.js"></script>
<script src="../notes-sidebar.js"></script>
</body>
</html>
 
